



For Immediate Release

Relora® Significantly Reduces Stress, Anxiety

Study Findings to be Presented at the FASEB in San Francisco

March 30, 2006 - Carlsbad, CA – Next Pharmaceuticals, Inc. (NPI) announced today that the results of an exciting new study on Relora® and its anti-anxiety properties will be presented in a poster session (C690) at the Federation of American Societies for Experimental Biology (FASEB) Conference in San Francisco on Sunday, April 2nd. Douglas S. Kalman, MS, RD, FACN, director of clinical research, at Miami Research Associates will reveal the details of the study at the Moscone Center from 12:45 to 3 PM.

“This conference is the “Academy Award” Conference of the scientific community, said Bob Garrison, president and CEO of Next Pharmaceuticals, Inc. “It’s a prestigious honor to be chosen by our peers to present the findings of our study on Relora® and we are delighted that we can play a vital part in helping to reduce anxiety for people who want a natural product as a first approach. The findings of this study validate that we have developed an important remedy that is safe, natural and effective.”

The Relora® randomized, placebo-controlled, parallel-group, clinical trial was conducted to assess the safety and efficacy of the formulation in reducing anxiety. The study enrolled 40 healthy, overweight, physically active, 25-50 year old women with anxiety. Subjects were randomized (1:1) to receive either placebo or 750 mg of Relora® for 6 weeks. An intent-to-treat analysis indicated that the Spielberger Trait Total and Anxiety Index scores improved significantly, and by twice as much with Relora® as with placebo ($p=0.047$). The Relora® group also had twice as much average reduction in sleep latency (11 minutes, $p=0.012$) as the placebo group (5 minutes, $p=0.147$). Most importantly, the formulation was found to significantly reduce anxiety and stress.

“Up until now, there has been no natural formula that has shown such significant results in reducing anxiety,” said Garrison. “People who are using Relora®, appreciate it as an effective formula that helps them deal with the stress and tension in their lives.”

About Next Pharmaceuticals, Inc.

Next Pharmaceuticals, Inc. is a research and development company that markets its patented or patent-pending ingredients such as Relora®, Nexrutine®, Seditol® and Citri-Z™ to food, beverage, and dietary supplement companies seeking differentiation and a marketing edge with their healthy living products.

About FASEB

Founded in 1912 by three societies, FASEB has consistently provided educational meetings and publications to disseminate biological research results. The then six member societies met in 1989 to alter its focus and to reaffirm its mission. The Federation has since experienced significant exponential growth.

Media Contact: Connie St John, 415-454-2243, 415-302-7438 (mobile) or connie@stjohnpr.com.

###